



Ellingjord-Dale, M., Papadimitriou, N., Ong, J. S., Elsworth, B. L., Lewis, S. J., & Martin, R. M. (2021). Coffee consumption and risk of breast cancer: a Mendelian Randomization study . *PLoS ONE*, 16(1), [e0236904]. <https://doi.org/10.1371/journal.pone.0236904>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.1371/journal.pone.0236904](https://doi.org/10.1371/journal.pone.0236904)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Public Library of Science at <https://doi.org/10.1371/journal.pone.0236904> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>


RESEARCH ARTICLE

Coffee consumption and risk of breast cancer: A Mendelian randomization study

Merete Ellingjord-Dale^{1*}, Nikos Papadimitriou², Michail Katsoulis³, Chew Yee¹, Niki Dimou², Dipender Gill¹, Dagfinn Aune^{1,4,5}, Jue-Sheng Ong^{6,7}, Stuart MacGregor⁶, Benjamin Elsworth⁷, Sarah J. Lewis^{7,8}, Richard M. Martin^{7,8,9}, Elio Riboli¹, Konstantinos K. Tsilidis^{1,10}

1 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom, **2** Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France, **3** Institute of Health Informatics Research, Faculty of Population Health Sciences, University College London, London, United Kingdom, **4** Department of Nutrition, Bjørknes University College, Oslo, Norway, **5** Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway, **6** Statistical Genetics, Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia, **7** MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom, **8** Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom, **9** National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, United Kingdom, **10** Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece

* m.ellingjord-dale@imperial.ac.uk



OPEN ACCESS

Citation: Ellingjord-Dale M, Papadimitriou N, Katsoulis M, Yee C, Dimou N, Gill D, et al. (2021) Coffee consumption and risk of breast cancer: A Mendelian randomization study. PLoS ONE 16(1): e0236904. <https://doi.org/10.1371/journal.pone.0236904>

Editor: Matteo Rota, Università degli Studi di Brescia, ITALY

Received: July 13, 2020

Accepted: January 3, 2021

Published: January 19, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0236904>

Copyright: © 2021 Ellingjord-Dale et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its [Supporting Information](#) files.

Abstract

Background

Observational studies have reported either null or weak protective associations for coffee consumption and risk of breast cancer.

Methods

We conducted a two-sample Mendelian randomization (MR) analysis to evaluate the relationship between coffee consumption and breast cancer risk using 33 single-nucleotide polymorphisms (SNPs) associated with coffee consumption from a genome-wide association (GWA) study on 212,119 female UK Biobank participants of White British ancestry. Risk estimates for breast cancer were retrieved from publicly available GWA summary statistics from the Breast Cancer Association Consortium (BCAC) on 122,977 cases (of which 69,501 were estrogen receptor (ER)-positive, 21,468 ER-negative) and 105,974 controls of European ancestry. Random-effects inverse variance weighted (IVW) MR analyses were performed along with several sensitivity analyses to assess the impact of potential MR assumption violations.

Results

One cup per day increase in genetically predicted coffee consumption in women was not associated with risk of total (IVW random-effects; odds ratio (OR): 0.91, 95% confidence intervals (CI): 0.80–1.02, P: 0.12, P for instrument heterogeneity: 7.17e-13), ER-positive

Funding: This work was supported by the World Cancer Research Fund International Regular Grant Programme (WCRF 2014/1180 to Konstantinos K. Tsilidis). RMM was supported by a Cancer Research UK (C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme) and is part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC_UU_12013/1, MC_UU_12013/2, and MC_UU_12013/3) and the University of Bristol. RMM is also supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National Institute for Health Research (NIHR) and is a partnership between University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: BMI, body mass index; BCAC, the Breast Cancer Association Consortium; CI, Confidence interval; ER, estrogen receptor; GWA, Genome-wide association; IVW, Inverse variance weighted; MR, Mendelian randomization; OR, Odds ratio; SNP, single-nucleotide polymorphism; UKB, UK Biobank.

(OR = 0.90, 95% CI: 0.79–1.02, P: 0.09) and ER-negative breast cancer (OR: 0.88, 95% CI: 0.75–1.03, P: 0.12). Null associations were also found in the sensitivity analyses using MR-Egger (total breast cancer; OR: 1.00, 95% CI: 0.80–1.25), weighted median (OR: 0.97, 95% CI: 0.89–1.05) and weighted mode (OR: 1.00, CI: 0.93–1.07).

Conclusions

The results of this large MR study do not support an association of genetically predicted coffee consumption on breast cancer risk, but we cannot rule out existence of a weak association.

Background

Coffee contains biochemical compounds such as caffeine, polyphenols and diterpenes that may protect against breast cancer risk through their anticarcinogenic properties [1–3] or through their favorable alterations of levels of estradiol and SHBG [4–8]. Several observational studies have investigated the association between coffee consumption and breast cancer risk, but findings have been inconsistent with the majority of studies reporting null associations [9–25] and other studies reporting protective associations [26–30]. A recent meta-analysis including 21 prospective cohort studies reported a weak protective association for highest versus lowest category of coffee consumption with overall (RR = 0.96, 95% CI = 0.93–1.00) and postmenopausal (RR = 0.92, 95% CI = 0.88–0.98) breast cancer [31]. However, observational studies may be confounded by other dietary or lifestyle factors. Further, there are no clinical trials on the effect of coffee consumption on breast cancer risk, and it is still unclear whether an association exists and if so, whether it is causal.

Several genome-wide association studies (GWAS) on coffee or caffeine consumption have been previously published [32–37]. One of these GWAS was a meta-analysis conducted by the Coffee and Caffeine Genetics Consortium in 2015 incorporating summary statistics from 28 population-based studies of European ancestry, and reported six loci associated with coffee consumption that were involved either in the pharmacokinetics (cytochrome P4501A1 (CYP1A1)/cytochrome P4501A2 (CYP1A2), aryl hydrocarbon receptor (AHR)) or pharmacodynamics of caffeine (brain-derived neurotrophic factor (BDNF) and solute carrier family 6 member 4 (SLC6A4)) [35]. A more recent and larger GWAS was conducted among individuals (179,954 males and 212,119 females) of white British ancestry in the UK Biobank (UKB) cohort [37], and identified 35 genetic variants strongly associated with coffee intake.

Mendelian randomization (MR) is a method that uses genetic variation arising from meiosis as a natural experiment, to investigate the potential causal relationship between an exposure and an outcome [38, 39]. MR estimates are less susceptible to bias from potential reverse causality and confounding compared to estimates from observational studies, because genetic variants are randomly distributed at conception [40, 41]. A recent MR study assessed the potential causal association between coffee consumption and risk of several cancers, including breast cancer, and concluded that coffee consumption is unlikely to be associated with overall breast cancer susceptibility [37]. However, the latter study did not report associations by breast cancer subtypes. In the current MR study, we investigated the relationship between genetically predicted coffee consumption and risk of breast cancer overall as well as breast cancer subtypes incorporating several MR methods to assess the impact of potential MR assumption violations.

Methods

Genetic data on coffee consumption

We used 35 single nucleotide polymorphisms (SNPs) that were associated with coffee consumption at genome-wide significance ($p < 5e-8$) level in the combined population of men and women in UKB [37], but their beta estimates (SNP-coffee) were derived from analyses only among the female population. In a sensitivity analysis, we combined beta estimates (SNP-coffee) for both men and women to increase statistical power. The UKB is a population-based cohort study of more than 500,000 participants aged 38 to 73 years, who enrolled in the study between 2006 and 2010 from across the UK [42]. Coffee consumption was measured via self-administered questionnaires and was defined as cups of decaffeinated coffee, instant coffee, ground coffee and any other type of coffee (UKB Data field ID: 1508) consumed per day [37]. Briefly, the UKB participants were genotyped using Affymetrix UK Biobank Axiom array and imputed against the UK10K, 1000 Genomes Phase 3 and Haplotype Reference Consortium panels [37]. The GWAS was conducted using the BOLT-LMM software [43] to model the genetic association accounting for cryptic relatedness in the UKB sample. SNPs were clumped at $r^2 < 0.01$ using a 10-mb window [37].

Genetic data on breast cancer

Out of the 35 genome-wide significant SNPs [37], we extracted 33 SNPs from the publicly available breast cancer GWAS from the Breast Cancer Association Consortium (BCAC). BCAC has data on 122,977 breast cancer cases of which 69,501 were estrogen receptor (ER)-positive, 21,468 ER-negative, and 105,974 controls of European ancestry (<http://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/gwas-icogs-and-oncoarray-summary-results/>). BCAC was initiated in 2005 and is an international collaboration that studies genetic susceptibility to breast cancer. The breast cancer GWAS was performed in females of European ancestry from 68 studies collaborating in BCAC, the Discovery, Biology and Risk of Inherited Variants in Breast Cancer Consortium (DRIVE; 61,282 cases and 45,494 controls), the Illumina iSelect genotyping Collaborative Oncological Gene-Environment Study (iCOGS; 46,785 cases and 42,892 controls), and 11 other breast cancer GWAS (14,910 cases and 17,588 controls) [44]. Genotyping in the BCAC and DRIVE studies was done using OncoArray1, whereas iCOGS used Illumina iSelect array (<http://ccge.medschl.cam.ac.uk/research/consortia/icogs/>). Using the 1000 Genomes Project (Phase 3) reference panel, genotypes were imputed for approximately 21M variants [44].

Statistical power

Statistical power calculations were conducted using the online mRnd calculator (available at <http://cnsngenomics.com/shiny/mRnd/>). Using an estimated 1% variance of coffee consumption explained by the instruments [37], the study had 80% power with a type I error rate of 0.05 to detect associations of odds ratios of 0.89, 0.87 and 0.80 per one cup of coffee per day and risk of overall, ER-positive and ER-negative breast cancer, respectively.

Statistical analysis

Main MR analysis. We conducted a two-sample MR using summary association data for 33 coffee-associated SNPs. We ran both fixed- and random-effects inverse-variance weighted (IVW) models, but the random-effects IVW model was considered the main analysis due to the large number of SNPs and the substantive observed heterogeneity [45, 46]. The IVW MR approach combines individual MR estimates across SNPs to derive an overall weighted

estimate of the potential causal effect. We calculated the MR-derived odds ratio (OR) of breast cancer risk for a one cup per day increase in genetically predicted coffee consumption. This study used publicly available data.

Sensitivity analyses. The IVW MR approach assumes that all genetic variants must satisfy the instrumental variable assumptions, namely the genetic variants must be: 1) associated with coffee consumption, 2) not associated with confounders of the association between coffee consumption and breast cancer, and 3) only associated with breast cancer via their association with coffee consumption [45, 47, 48]. We tested for potential violation of the first MR assumption by measuring the strength of the genetic instruments using F-statistics. The F-statistic is the ratio of the mean square of the model to the mean square of error [49]. The Cochran's Q test and the I^2 statistic were used to quantify the heterogeneity in effect sizes between the genetic instruments [50], which may indicate horizontal pleiotropy that could violate the third MR assumption. To further test and attempt to correct for potential violation of the second and third MR assumptions, we used several approaches such as the MR-Egger regression [51], the weighted median [52] and mode [53] methods, and the MR pleiotropy residual sum and outlier test (MR-PRESSO) [54].

MR-Egger. The MR-Egger is an adaption of Egger regression, which allows for directional pleiotropy by introducing an intercept in the weighted regression model. Values away from zero for the intercept term are an indication of horizontal pleiotropy [51]. The MR-Egger approach provides unbiased results in the presence of pleiotropic instruments assuming that the magnitude of pleiotropic effects is independent of the size of the SNP-coffee consumption effects, which is called the Instrument Strength Independent of Direct Effects (InSIDE) assumption [51].

Weighted median. We used the weighted median method that orders the MR estimates obtained using each instrument weighted for the inverse of their variance. Selecting the median result provides a single MR estimate with confidence intervals estimated using a parametric bootstrap method [52]. The weighted median does not require that the size of any pleiotropic effects on the instruments are uncorrelated to their effects on the intermediate phenotype, but assumes that at least half of the instruments are valid [55].

Weighted mode. The mode based causal estimate consistently estimates the true causal effect when the largest group of instruments with consistent MR estimates is valid [53].

MR-PRESSO. We used the MR-PRESSO outlier test to identify outlier SNPs, which could have pleiotropic effects [54]. This method regresses SNP-outcome on SNP-exposure and uses square of residuals to identify outliers.

To further determine whether pleiotropy could have influenced our results, we collected information on published associations of the genetic instruments for coffee consumption with other phenotypes from the Phenoscanner webpage [56]. Genetic instruments associated at genome-wide significance with potentially important confounders of the coffee and breast cancer association, namely BMI [57–61], age at menarche [62, 63], alcohol [64–68], smoking [67, 69–71] and age at menopause [72] were iteratively excluded from the analyses.

In addition, we repeated the analysis after excluding SNPs that had p-values in their associations with coffee consumption among women larger than $1e-05$ to avoid weak instrument bias. We also used beta estimates from a previous GWAS as an alternative instrument of eight SNPs (rs1260326, rs1481012, rs17685, rs7800944, rs6265, rs9902453, rs2472297 and rs4410790) associated with coffee consumption [35] to ensure that our results were robust against different choices of instrument selection and because these eight SNPs are linked to caffeine metabolism and may reflect less likelihood for pleiotropic actions. All the analyses were performed using the MR robust package in Stata [73] and the Mendelian randomization package in R [74].

Results

The associations between the genetic instruments with coffee consumption and breast cancer are shown in the [S1 Table](#). One variant (rs17817964 in *FTO*) was strongly associated with overall ($P = 4.67\text{E-}20$), ER-positive ($P = 2.48\text{E-}13$) and ER-negative breast cancer ($P = 1.56\text{E-}09$).

Main MR analyses

The fixed-effects IVW method yielded inverse associations for genetically predicted coffee intake and risk of total, ER-positive and ER-negative breast cancer (Figs 1–3 and [S2 Table](#)), but there was substantial heterogeneity in the individual SNPs instrumenting coffee and risk of disease (Cochran's Q test P -value = 10^{-5} – 10^{-13} , $I^2 = 57$ – 74% , [S1–S6 Figs](#)). Therefore, the random-effects IVW model was preferentially adopted for the main analysis, where the association between coffee consumption (per cup of coffee per day) and total (OR = 0.91, 95% CI = 0.80–1.02, $P = 0.12$), ER-positive (OR = 0.90, 95% CI = 0.79–1.02, $P = 0.09$) and ER-negative breast cancer (OR = 0.88, 95% CI = 0.75–1.03, $P = 0.12$) resulted in wider confidence intervals overlapping the null (Figs 1–3 and [S2 Table](#)).

MR-Egger

Results based on the MR-Egger regression did not show any association for genetically predicted coffee consumption and risk of total breast cancer or subtypes (Figs 1–3, [S2 Table](#)).

Weighted median and mode

Similarly, results from the weighted median analysis showed little evidence of an association per one cup of coffee per day and overall (OR = 0.97, 95% CI = 0.89–1.05, $P = 0.45$, [Fig 1](#)), ER-positive (OR = 0.94, 95% CI = 0.86–1.04, $P = 0.24$, [Fig 2](#)) and ER-negative breast cancer (OR = 1.02, 95% CI = 0.90–1.17, $P = 0.72$, [Fig 3](#)). The weighted mode model also yielded little evidence for an association (Overall breast cancer; OR = 1.00, 95% CI = 0.93–1.07, Figs 1–3 and [S2 Table](#)).

MR-PRESSO

The MR-PRESSO outlier test detected six SNPs as potential outliers for total breast cancer (i.e. rs13387939, rs17817964, rs34060476, rs2472297, rs2521501 and rs539515), three SNPs for ER-positive breast cancer (i.e. rs17817964, rs2472297 and rs2521501) and three SNPs for ER-negative breast cancer (i.e. rs13387939, rs3810291 and rs17817964). After excluding these SNPs outliers, there was an inverse association between genetically predicted coffee intake (per one cup of coffee per day) and risk of overall (OR = 0.90, 95% CI = 0.83–0.98, $P = 0.03$) and ER-positive breast cancer (OR = 0.87, 95% CI = 0.78–0.97, $P = 0.02$), but no association for ER-negative breast cancer (OR = 0.97, 95% CI = 0.87–1.08, $P = 0.62$, [S2 Table](#)). However, the rs2472297 is located between *CYP1A1* and *CYP1A2* and is involved in the pharmacokinetics of caffeine, and has the strongest association with coffee consumption amongst all genetic instruments ($P < 1\text{e-}168$). Many of the other outlying SNPs had genome-wide significant associations with age at menarche (rs17817964, rs13387939, rs539515 and rs3810291), body mass index (rs17817964, rs13387939, rs2472297, rs539515 and rs3810291) and alcohol intake (rs17817964 and rs34060476, [S3 Table](#)).

Sensitivity analyses

We performed several sensitivity analyses and there was little evidence of any association between genetically predicted coffee consumption and breast cancer risk ([S2 Table](#)). We




Fig 1. Association between 1 cup/day increase of coffee consumption and breast cancer risk overall. MR-analyses are derived using random effect IVW, MR-Egger, weighted median and mode.

<https://doi.org/10.1371/journal.pone.0236904.g001>

performed MR-analyses after excluding genetic instruments known to be associated at genome-wide significance with 1) body mass index (i.e. rs4357572, rs539515, rs62106258, rs13387939, rs142219, rs2465054, rs4410790, rs2472297, rs17817964, rs66723169 and rs3810291), 2) age at menarche (i.e. rs539515, rs62106258, rs13387939, rs2236955, rs17817964 and rs381029), 3) alcohol consumption (i.e. rs1260326, rs34060476, rs17817964 and rs66723169), 4) smoking (i.e. rs56113850), and 5) age at menopause (i.e. rs1260326) (S2 and S3 Tables). When we reran the analyses after excluding 13 genetic instruments (i.e.




Fig 2. Association between 1 cup/day increase of coffee consumption and risk of ER-positive breast cancer. MR-analyses are derived using random effect IVW, MR-Egger, weighted median and mode.

<https://doi.org/10.1371/journal.pone.0236904.g002>

rs117968677, rs1260326, rs1422191, rs16966903, rs2236955, rs2465054, rs2667773, rs34190000, rs3810291, rs395815, rs4092465, rs55754437 and rs62064918) with p-values with coffee consumption among women larger than 10^{-5} , the results remained largely the same (Overall; OR = 0.90, 95% CI 0.77–1.06, ER-positive; OR = 0.99, 95% CI 0.77–1.05 and ER-negative; OR = 0.88, 95% CI 0.72–1.07, [S2 Table](#)). In another sensitivity analysis, we used as genetic instruments eight SNPs (i.e. rs1260326, rs1481012, rs17685, rs7800944, rs6265, rs9902453, rs4410790 and rs2472297) from a GWAS for coffee consumption among




Fig 3. Association between 1 cup/day increase of coffee consumption and risk of ER-negative breast cancer. MR-analyses are derived using random effect IVW, MR-Egger, weighted median and mode.

<https://doi.org/10.1371/journal.pone.0236904.g003>

consumers conducted by the Coffee and Caffeine Genetics Consortium [35], and there was again no evidence of an association (Overall; OR = 1.10, 95% CI 0.97–1.24, ER-positive; OR = 1.07, 95% CI 0.96–1.21 and ER-negative; OR = 1.16, 95% CI 0.97–1.38). To increase statistical power, we used the 33 genetic instruments from UK Biobank but with beta estimates (SNP-coffee) from females and males combined, but the results remained largely the same (Overall; OR = 0.92, 95% CI 0.82–1.04, $P = 0.20$, ER-positive; OR = 0.92, 95% CI 0.81–1.04, $P = 0.16$, ER-negative; OR = 0.90, 95% CI 0.77–1.05, $P = 0.17$, S2 Table).

Discussion

In this comprehensive MR analysis of coffee consumption with risk of breast cancer, we observed that in the majority of analyses genetically predicted consumption of coffee was not associated with overall, ER-positive and ER-negative breast cancer. In line with our results, a recent large MR-study on the association between coffee consumption and risk of being diagnosed with or dying from cancer overall and by anatomical subsite reported no evidence for an association with risk of breast cancer [37]. Compared to the previous study, our study added results by ER-status and presented detailed sensitivity analyses to fully assess potential violations of MR assumptions.

Coffee is among the most commonly consumed beverages worldwide, and its drinking provides exposure to a range of biologically active compounds [75]. Higher coffee consumption has been associated with decreased risk of all-cause, cardiovascular and cancer mortality among non-smokers [76]. Several observational studies have investigated the association between coffee consumption and risk of breast cancer development, but findings have been inconsistent [31, 77, 78]. The most recent meta-analysis synthesized evidence from 21 prospective cohort studies [31], and reported a weak inverse association between coffee consumption and risk of total (OR higher vs. lower = 0.96, 95% CI = 0.93–1.00) and postmenopausal breast cancer (OR = 0.92, 95% CI = 0.88–0.98). Null associations were reported by estrogen or progesterone receptor status [31]. When a dose-response meta-analysis was conducted among 13 prospective studies [31], the association per one cup of coffee per day was nominally significant (OR for postmenopausal disease = 0.97, 95% CI = 0.95–1.00), which was consistent with the finding of the current MR study (OR = 0.90, 95% CI 0.79–1.02). In agreement, the World Cancer Research Fund Third Expert Report graded the evidence of coffee consumption and breast cancer risk as limited-no conclusion [79].

MR studies can be useful in nutritional epidemiology, as they are less susceptible to biases that are commonly present in traditional observational literature [80], namely exposure measurement error, residual confounding and reverse causation. MR estimates warrant a causal interpretation only if the assumptions of the instrumental variable approach hold. Though it is not possible to prove the validity of the assumptions in entirety, we performed several sensitivity analyses to detect potential violations and derived estimates that are potentially robust against violations of these assumptions. The majority of the sensitivity analyses supported our main analysis finding.

Several limitations should be considered when interpreting our findings. Our MR-analysis had appropriate statistical power to detect an OR of 0.89 per cup of coffee per day and risk of overall breast cancer. Observational studies have detected smaller associations of coffee consumption and breast cancer risk than this [31]. We were unable to rule out the possibility that coffee consumption may have a weaker association that we were not powered to detect. A weakness of using summary level data in two-sample MR is that stratified analyses by covariates of interest (e.g. smoking, alcohol, obesity, physical activity) are not possible which would have allowed us to investigate potential interactions between risk factors, but previous observational studies have in general not identified interactions with these variables [31]. Although we have involved clinically meaningful disease subtypes such as ER+ /– breast cancer, we could not examine breast cancer based on menopause status but 85% of breast cancer cases in our sample are postmenopausal. Although our genetic instruments are robustly associated with coffee consumption, coffee consumption itself is a heterogeneous phenotype that may potentially limit the generalizability of our findings on specific coffee type or preparation procedure. In addition, we are currently unable to isolate and classify genetic variants into caffeine and non-caffeine aspects of coffee given that the genetic loci heavily overlap, and future research

into the biological mechanisms of the genetic instruments is warranted when more data becomes available; until then, a potential role of micronutrients attained through coffee consumption on reduction of breast cancer risk cannot be ruled out. Another limitation was that two-sample MR assumes linearity, so we could not evaluate potential existence of non-linear associations.

Conclusions

In summary, the results of this large MR study do not support an association of genetically predicted coffee consumption on breast cancer risk, but we cannot rule out existence of a weak association.

Supporting information

S1 Fig.
(JPG)

S2 Fig.
(JPG)

S3 Fig.
(JPG)

S4 Fig.
(JPG)

S5 Fig.
(JPG)

S6 Fig.
(JPG)

S1 Table. Univariate mendelian randomization analyses of coffee consumption genetic variants and breast cancer.
(XLSX)

S2 Table. Characteristics of genetic variants associated with coffee consumption and breast cancer overall and subtypes.
(XLSX)

S3 Table. SNPs associated with secondary traits using Phenoscanner (<http://www.phenoscanner.medschl.cam.ac.uk/upload/>).
(XLSX)

Acknowledgments

Disclaimer: Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization.

Author Contributions

Conceptualization: Konstantinos K. Tsilidis.

Data curation: Merete Ellingjord-Dale, Michail Katsoulis, Jue-Sheng Ong, Stuart MacGregor, Benjamin Elsworth.

Formal analysis: Merete Ellingjord-Dale, Chew Yee.

Funding acquisition: Konstantinos K. Tsilidis.

Investigation: Merete Ellingjord-Dale, Nikos Papadimitriou, Chew Yee, Niki Dimou.

Methodology: Merete Ellingjord-Dale, Nikos Papadimitriou, Chew Yee, Dipender Gill, Jue-Sheng Ong, Stuart MacGregor, Benjamin Elsworth, Sarah J. Lewis, Richard M. Martin.

Project administration: Konstantinos K. Tsilidis.

Resources: Konstantinos K. Tsilidis.

Supervision: Konstantinos K. Tsilidis.

Writing – original draft: Merete Ellingjord-Dale.

Writing – review & editing: Merete Ellingjord-Dale, Nikos Papadimitriou, Michail Katsoulis, Niki Dimou, Dipender Gill, Dagfinn Aune, Jue-Sheng Ong, Stuart MacGregor, Benjamin Elsworth, Sarah J. Lewis, Richard M. Martin, Elio Riboli, Konstantinos K. Tsilidis.

References

1. Nkondjock A. Coffee consumption and the risk of cancer: an overview. *Cancer Lett.* 2009; 277(2):121–5. <https://doi.org/10.1016/j.canlet.2008.08.022> PMID: 18834663
2. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. *Food Chem Toxicol.* 2002; 40(8):1155–63. [https://doi.org/10.1016/S0278-6915\(02\)00029-7](https://doi.org/10.1016/S0278-6915(02)00029-7) PMID: 12067578
3. Grosso G, Godos J, Lamuela-Raventos R, Ray S, Micek A, Pajak A, et al. A comprehensive meta-analysis on dietary flavonoid and lignan intake and cancer risk: Level of evidence and limitations. *Mol Nutr Food Res.* 2017; 61(4). <https://doi.org/10.1002/mnfr.201600930> PMID: 27943649
4. Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C, et al. Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. *Endocr Relat Cancer.* 2010; 17(1):125–34. <https://doi.org/10.1677/ERC-09-0211> PMID: 19903744
5. Kotsopoulos J, Eliassen AH, Missmer SA, Hankinson SE, Tworoger SS. Relationship between caffeine intake and plasma sex hormone concentrations in premenopausal and postmenopausal women. *Cancer-Am Cancer Soc.* 2009; 115(12):2765–74. <https://doi.org/10.1002/cncr.24328> PMID: 19384973
6. Fung TT, Schulze MB, Hu FB, Hankinson SE, Holmes MD. A dietary pattern derived to correlate with estrogens and risk of postmenopausal breast cancer. *Breast Cancer Res Treat.* 2012; 132(3):1157–62. <https://doi.org/10.1007/s10549-011-1942-z> PMID: 22218885
7. Sisti JS, Hankinson SE, Caporaso NE, Gu F, Tamimi RM, Rosner B, et al. Caffeine, coffee, and tea intake and urinary estrogens and estrogen metabolites in premenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2015; 24(8):1174–83. <https://doi.org/10.1158/1055-9965.EPI-15-0246> PMID: 26063478
8. Nagata C, Kabuto M, Shimizu H. Association of coffee, green tea, and caffeine intakes with serum concentrations of estradiol and sex hormone-binding globulin in premenopausal Japanese women. *Nutr Cancer.* 1998; 30(1):21–4. <https://doi.org/10.1080/01635589809514635> PMID: 9507508
9. Folsom AR, McKenzie DR, Bisgard KM, Kushi LH, Sellers TA. No association between caffeine intake and postmenopausal breast cancer incidence in the Iowa Women's Health Study. *Am J Epidemiol.* 1993; 138(6):380–3. <https://doi.org/10.1093/oxfordjournals.aje.a116870> PMID: 8213743
10. Boggs DA, Palmer JR, Stampfer MJ, Spiegelman D, Adams-Campbell LL, Rosenberg L. Tea and coffee intake in relation to risk of breast cancer in the Black Women's Health Study. *Cancer Causes Control.* 2010; 21(11):1941–8. <https://doi.org/10.1007/s10552-010-9622-6> PMID: 20680436
11. Larsson SC, Bergkvist L, Wolk A. Coffee and black tea consumption and risk of breast cancer by estrogen and progesterone receptor status in a Swedish cohort. *Cancer Causes Control.* 2009; 20(10):2039–44. <https://doi.org/10.1007/s10552-009-9396-x> PMID: 19597749

12. Gierach GL, Freedman ND, Andaya A, Hollenbeck AR, Park Y, Schatzkin A, et al. Coffee intake and breast cancer risk in the NIH-AARP diet and health study cohort. *Int J Cancer*. 2012; 131(2):452–60. <https://doi.org/10.1002/ijc.26372> PMID: 22020403
13. Fagherazzi G, Touillaud MS, Boutron-Ruault MC, Clavel-Chapelon F, Romieu I. No association between coffee, tea or caffeine consumption and breast cancer risk in a prospective cohort study. *Public Health Nutr*. 2011; 14(7):1315–20. <https://doi.org/10.1017/S1368980011000371> PMID: 21466740
14. McLaughlin CC, Mahoney MC, Nasca PC, Metzger BB, Baptiste MS, Field NA. Breast cancer and methylxanthine consumption. *Cancer Causes Control*. 1992; 3(2):175–8. <https://doi.org/10.1007/BF00051658> PMID: 1562707
15. Bhoo-Pathy N, Peeters PHM, Uiterwaal CSPM, Bueno-De-Mesquita HB, Bulgiba AM, Bech BH, et al. Coffee and tea consumption and risk of pre- and postmenopausal breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. *Breast Cancer Research*. 2015;17. <https://doi.org/10.1186/s13058-015-0523-1> PMID: 25849559
16. Michels KB, Holmberg L, Bergkvist L, Wolk A. Coffee, tea, and caffeine consumption and breast cancer incidence in a cohort of Swedish women. *Ann Epidemiol*. 2002; 12(1):21–6. [https://doi.org/10.1016/s1047-2797\(01\)00238-1](https://doi.org/10.1016/s1047-2797(01)00238-1) PMID: 11750236
17. Ganmaa D, Willett WC, Li TY, Feskanich D, van Dam RM, Lopez-Garcia E, et al. Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up. *Int J Cancer*. 2008; 122(9):2071–6. <https://doi.org/10.1002/ijc.23336> PMID: 18183588
18. Bhoo Pathy N, Peeters P, van Gils C, Beulens JW, van der Graaf Y, Bueno-de-Mesquita B, et al. Coffee and tea intake and risk of breast cancer. *Breast Cancer Res Treat*. 2010; 121(2):461–7. <https://doi.org/10.1007/s10549-009-0583-y> PMID: 19847643
19. Vatten LJ, Solvoll K, Loken EB. Coffee consumption and the risk of breast cancer. A prospective study of 14,593 Norwegian women. *Br J Cancer*. 1990; 62(2):267–70. <https://doi.org/10.1038/bjc.1990.274> PMID: 2386741
20. Lubin F, Ron E, Wax Y, Modan B. Coffee and methylxanthines and breast cancer: a case-control study. *J Natl Cancer Inst*. 1985; 74(3):569–73. PMID: 3856060
21. Ewertz M, Gill C. Dietary factors and breast-cancer risk in Denmark. *Int J Cancer*. 1990; 46(5):779–84. <https://doi.org/10.1002/ijc.2910460505> PMID: 2228305
22. Mannisto S, Pietinen P, Virtanen M, Kataja V, Uusitupa M. Diet and the risk of breast cancer in a case-control study: does the threat of disease have an influence on recall bias? *J Clin Epidemiol*. 1999; 52(5):429–39. [https://doi.org/10.1016/s0895-4356\(99\)00010-4](https://doi.org/10.1016/s0895-4356(99)00010-4) PMID: 10360338
23. Hirvonen T, Mennen LI, de Bree A, Castetbon K, Galan P, Bertrais S, et al. Consumption of antioxidant-rich beverages and risk for breast cancer in French women. *Ann Epidemiol*. 2006; 16(7):503–8. <https://doi.org/10.1016/j.annepidem.2005.09.011> PMID: 16406814
24. Rosenberg L, Miller DR, Helmrigh SP, Kaufman DW, Schottenfeld D, Stolley PD, et al. Breast cancer and the consumption of coffee. *Am J Epidemiol*. 1985; 122(3):391–9. <https://doi.org/10.1093/oxfordjournals.aje.a114120> PMID: 4025289
25. La Vecchia C, Talamini R, Decarli A, Franceschi S, Parazzini F, Tognoni G. Coffee consumption and the risk of breast cancer. *Surgery*. 1986; 100(3):477–81. PMID: 3738766
26. Nilsson LM, Johansson I, Lenner P, Lindahl B, Van Guelpen B. Consumption of filtered and boiled coffee and the risk of incident cancer: a prospective cohort study. *Cancer Causes Control*. 2010; 21(10):1533–44. <https://doi.org/10.1007/s10552-010-9582-x> PMID: 20512657
27. Baker JA, Beehler GP, Sawant AC, Jayaprakash V, McCann SE, Moysich KB. Consumption of coffee, but not black tea, is associated with decreased risk of premenopausal breast cancer. *J Nutr*. 2006; 136(1):166–71. <https://doi.org/10.1093/jn/136.1.166> PMID: 16365077
28. Li J, Seibold P, Chang-Claude J, Flesch-Janys D, Liu J, Czene K, et al. Coffee consumption modifies risk of estrogen-receptor negative breast cancer. *Breast Cancer Res*. 2011; 13(3):R49. <https://doi.org/10.1186/bcr2879> PMID: 21569535
29. Oh JK, Sandin S, Strom P, Lof M, Adami HO, Weiderpass E. Prospective study of breast cancer in relation to coffee, tea and caffeine in Sweden. *Int J Cancer*. 2015; 137(8):1979–89. <https://doi.org/10.1002/ijc.29569> PMID: 25885188
30. Lukic M, Licaj I, Lund E, Skeie G, Weiderpass E, Braaten T. Coffee consumption and the risk of cancer in the Norwegian Women and Cancer (NOWAC) Study. *Eur J Epidemiol*. 2016; 31(9):905–16. <https://doi.org/10.1007/s10654-016-0142-x> PMID: 27010635
31. Lafranchi A, Micek A, De Paoli P, Bimonte S, Rossi P, Quagliarile V, et al. Coffee Intake Decreases Risk of Postmenopausal Breast Cancer: A Dose-Response Meta-Analysis on Prospective Cohort Studies. *Nutrients*. 2018; 10(2). <https://doi.org/10.3390/nu10020112> PMID: 29360766

32. Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KKH, et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. *Hum Mol Genet.* 2011; 20(10):2071–7. <https://doi.org/10.1093/hmg/ddr086> PMID: 21357676
33. Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN, et al. Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption. *Plos Genet.* 2011; 7(4).
34. Amin N, Byrne E, Johnson J, Chenevix-Trench G, Walter S, Nolte IM, et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. *Mol Psychiatr.* 2012; 17(11):1116–29. <https://doi.org/10.1038/mp.2011.101> PMID: 21876539
35. Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A, Paynter N, et al. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. *Mol Psychiatr.* 2015; 20(5):647–56. <https://doi.org/10.1038/mp.2014.107> PMID: 25288136
36. Pirastu N, Kooyman M, Robino A, van der Spek A, Navarini L, Amin N, et al. Non-additive genome-wide association scan reveals a new gene associated with habitual coffee consumption. *Sci Rep-Uk.* 2016; 6. <https://doi.org/10.1038/srep31590> PMID: 27561104
37. Ong JS, Law MH, An JY, Han XK, Gharahkhani P, Whiteman DC, et al. Association between coffee consumption and overall risk of being diagnosed with or dying from cancer among > 300 000 UKBio-bank participants in a large-scale Mendelian randomization study. *Int J Epidemiol.* 2019; 48(5):1447–56. <https://doi.org/10.1093/ije/dyz144> PMID: 31412118
38. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet.* 2014; 23:R89–R98. <https://doi.org/10.1093/hmg/ddu328> PMID: 25064373
39. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ.* 2018; 362:k601. <https://doi.org/10.1136/bmj.k601> PMID: 30002074
40. Palmer TM, Sterne JA, Harbord RM, Lawlor DA, Sheehan NA, Meng S, et al. Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. *Am J Epidemiol.* 2011; 173(12):1392–403. <https://doi.org/10.1093/aje/kwr026> PMID: 21555716
41. Verduijn M, Siegerink B, Jager KJ, Zoccali C, Dekker FW. Mendelian randomization: use of genetics to enable causal inference in observational studies. *Nephrol Dial Transplant.* 2010; 25(5):1394–8. <https://doi.org/10.1093/ndt/gfq098> PMID: 20190244
42. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* 2015; 12(3):e1001779. <https://doi.org/10.1371/journal.pmed.1001779> PMID: 25826379
43. Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjalmsdottir BJ, Finucane HK, Salem RM, et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat Genet.* 2015; 47(3):284–90. <https://doi.org/10.1038/ng.3190> PMID: 25642633
44. Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. *Nature.* 2017; 551(7678):92–4. <https://doi.org/10.1038/nature24284> PMID: 29059683
45. Burgess S TS. *Mendelian Randomization: Methods for Using Genetic Variants in Causal Estimation.* 1st Edition ed. New York: Boca Raton, FL: CRC Press; 2015 6 March 2015.
46. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* 2013; 37(7):658–65. <https://doi.org/10.1002/gepi.21758> PMID: 24114802
47. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. *Stat Methods Med Res.* 2007; 16(4):309–30. <https://doi.org/10.1177/0962280206077743> PMID: 17715159
48. Greenland S. An introduction to instrumental variables for epidemiologists. *Int J Epidemiol.* 2018; 47(1):358. <https://doi.org/10.1093/ije/dyx275> PMID: 29294084
49. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. *Int J Epidemiol.* 2011; 40(3):740–52. <https://doi.org/10.1093/ije/dyq151> PMID: 20813862
50. Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. *Stat Med.* 2015; 34(21):2926–40. <https://doi.org/10.1002/sim.6522> PMID: 25950993
51. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol.* 2015; 44(2):512–25. <https://doi.org/10.1093/ije/dyv080> PMID: 26050253

52. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol.* 2016; 40(4):304–14. <https://doi.org/10.1002/gepi.21965> PMID: 27061298
53. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol.* 2017; 46(6):1985–98. <https://doi.org/10.1093/ije/dyx102> PMID: 29040600
54. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet.* 2018; 50(5):693–8. <https://doi.org/10.1038/s41588-018-0099-7> PMID: 29686387
55. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I² statistic. *Int J Epidemiol.* 2016; 45(6):1961–74. <https://doi.org/10.1093/ije/dyw220> PMID: 27616674
56. Phenoscanner. [Available from: <http://www.phenoscanner.medschl.cam.ac.uk>.
57. Heard-Costa NL, Zillikens MC, Monda KL, Johansson A, Harris TB, Fu M, et al. NRXN3 Is a Novel Locus for Waist Circumference: A Genome-Wide Association Study from the CHARGE Consortium. *Plos Genet.* 2009; 5(6). <https://doi.org/10.1371/journal.pgen.1000539> PMID: 19557197
58. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet.* 2010; 42(11):937–48. <https://doi.org/10.1038/ng.686> PMID: 20935630
59. Paternoster L, Evans DM, Nohr EA, Holst C, Gaborieau V, Brennan P, et al. Genome-wide population-based association study of extremely overweight young adults—the GOYA study. *PLoS One.* 2011; 6(9):e24303. <https://doi.org/10.1371/journal.pone.0024303> PMID: 21935397
60. Yang J, Loos RJF, Powell JE, Medland SE, Speliotes EK, Chasman DI, et al. FTO genotype is associated with phenotypic variability of body mass index. *Nature.* 2012; 490(7419):267–+. <https://doi.org/10.1038/nature11401> PMID: 22982992
61. Guo Y, Lanktree MB, Taylor KC, Hakonarson H, Lange LA, Keating BJ, et al. Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. *Hum Mol Genet.* 2013; 22(1):184–201. <https://doi.org/10.1093/hmg/ddc396> PMID: 23001569
62. Perry JRB, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature.* 2014; 514(7520):92–+. <https://doi.org/10.1038/nature13545> PMID: 25231870
63. Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, et al. Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *Am J Hum Genet.* 2019; 104(1):65–75. <https://doi.org/10.1016/j.ajhg.2018.11.008> PMID: 30595370
64. Clarke TK, Adams MJ, Davies G, Howard DM, Hall LS, Padmanabhan S, et al. Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N = 112 117). *Mol Psychiatry.* 2017; 22(10):1376–84. <https://doi.org/10.1038/mp.2017.153> PMID: 28937693
65. Evangelou E, Gao H, Chu C, Ntritsos G, Blakeley P, Butts AR, et al. New alcohol-related genes suggest shared genetic mechanisms with neuropsychiatric disorders. *Nat Hum Behav.* 2019; 3(9):950–61. <https://doi.org/10.1038/s41562-019-0653-z> PMID: 31358974
66. Zhong VW, Kuang A, Danning RD, Kraft P, van Dam RM, Chasman DI, et al. A genome-wide association study of bitter and sweet beverage consumption. *Hum Mol Genet.* 2019; 28(14):2449–57. <https://doi.org/10.1093/hmg/ddz061> PMID: 31046077
67. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet.* 2019; 51(2):237–44. <https://doi.org/10.1038/s41588-018-0307-5> PMID: 30643251
68. Karlsson Linner R, Biroli P, Kong E, Meddens SFW, Wedow R, Fontana MA, et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. *Nat Genet.* 2019; 51(2):245–57. <https://doi.org/10.1038/s41588-018-0309-3> PMID: 30643258
69. Brazel DM, Jiang Y, Hughey JM, Turcot V, Zhan X, Gong J, et al. Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use. *Biol Psychiatry.* 2019; 85(11):946–55. <https://doi.org/10.1016/j.biopsych.2018.11.024> PMID: 30679032
70. Patel YM, Park SL, Han Y, Wilkens LR, Bickeboller H, Rosenberger A, et al. Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. *Cancer Res.* 2016; 76(19):5768–76. <https://doi.org/10.1158/0008-5472.CAN-16-0446> PMID: 27488534

71. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat Genet.* 2017; 49(7):1126–32. <https://doi.org/10.1038/ng.3892> PMID: 28604730
72. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nat Genet.* 2015; 47(11):1294–303. <https://doi.org/10.1038/ng.3412> PMID: 26414677
73. Spiller W DN, Palmer T. Software Application Profile: mrrobust—A tool for performing two-sample summary Mendelian randomization analyses. *bioRxiv*, published online 25th May 2017.
74. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol.* 2017; 46(6):1734–9. <https://doi.org/10.1093/ije/dyx034> PMID: 28398548
75. Gomez-Ruiz JA, Leake DS, Ames JM. In vitro antioxidant activity of coffee compounds and their metabolites. *J Agr Food Chem.* 2007; 55(17):6962–9. <https://doi.org/10.1021/jf0710985> PMID: 17655324
76. Grosso G, Micek A, Godos J, Sciacca S, Pajak A, Martinez-Gonzalez MA, et al. Coffee consumption and risk of all-cause, cardiovascular, and cancer mortality in smokers and non-smokers: a dose-response meta-analysis. *Eur J Epidemiol.* 2016; 31(12):1191–205. <https://doi.org/10.1007/s10654-016-0202-2> PMID: 27699514
77. Li XJ, Ren ZJ, Qin JW, Zhao JH, Tang JH, Ji MH, et al. Coffee consumption and risk of breast cancer: an up-to-date meta-analysis. *PLoS One.* 2013; 8(1):e52681. <https://doi.org/10.1371/journal.pone.0052681> PMID: 23308117
78. Jiang W, Wu Y, Jiang X. Coffee and caffeine intake and breast cancer risk: an updated dose-response meta-analysis of 37 published studies. *Gynecol Oncol.* 2013; 129(3):620–9. <https://doi.org/10.1016/j.ygyno.2013.03.014> PMID: 23535278
79. Report TWCRFTE. Diet, nutrition, physical activity and breast cancer. <https://www.wcrf.org/sites/default/files/Breast-cancer-report.pdf>. 2017.
80. Schatzkin A, Abnet CC, Cross AJ, Gunter M, Pfeiffer R, Gail M, et al. Mendelian Randomization: How It Can-and Cannot-Help Confirm Causal Relations between Nutrition and Cancer. *Cancer Prev Res.* 2009; 2(2):104–13. <https://doi.org/10.1158/1940-6207.CAPR-08-0070> PMID: 19174578